Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Ibrutinib, a first-in-class covalent inhibitor of Bruton's tyrosine kinase (BTK), is approved in many countries for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) and for previously untreated disease with a 17p deletion and, most recently, as a frontline therapy for CLL. In controlled trials in CLL, ibrutinib produced high response rates and improved survival in both the frontline and relapsed settings. While ibrutinib controls CLL with impressive efficacy, it only infrequently induces complete remissions, particularly of relapsed CLL, and does not eradicate minimal residual disease. Finally, ibrutinib is extremely expensive, has off-target toxicities, and requires indefinite therapy. Areas covered: In this article, we provide an overview of the CLL therapeutic landscape and discuss the pharmacokinetic and pharmacodynamic aspects of ibrutinib. Major clinical trials of ibrutinib in CLL are summarized, and its safety profile explored. Expert opinion: Ibrutinib represents a transformative advance in CLL management and has validated BTK as a therapeutic target in this disease, but has some limitations, leading to the emergence of other BTK inhibitors and mechanism-based combination strategies. Given complete BTK occupancy at lower doses of ibrutinib and declining levels of BTK on ibrutinib therapy, lower doses of ibrutinib in CLL are being explored.
a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Prithviraj
P
Bose
a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.|b Department of Experimental Therapeutics , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Varsha V
VV
Gandhi
a Department of Leukemia , University of Texas MD Anderson Cancer Center , Houston , TX , USA.
Michael J
MJ
Keating
B-cell receptor; Bruton tyrosine kinase; chronic lymphocytic leukemia; dosing; ibrutinib; pharmacodynamics; pharmacokinetic
Blood. 2000 Mar 1;95(5):1663-70
10688822
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2737-42
10688914
J Exp Med. 2000 May 15;191(10):1735-44
10811866
J Exp Med. 2000 May 15;191(10):1745-54
10811867
Blood. 2003 Nov 15;102(10):3592-9
12842985
Nature. 2006 May 25;441(7092):431-6
16724054
Blood. 2006 Oct 15;108(8):2596-603
16788103
J Clin Invest. 2007 Jan;117(1):112-21
17200714
J Biol Chem. 2008 Apr 25;283(17):11189-98
18276597
Cell. 2008 Mar 7;132(5):794-806
18329366
Proc Natl Acad Sci U S A. 2010 Jul 20;107(29):13075-80
20615965
Blood. 2011 Jun 9;117(23):6287-96
21422473
Blood. 2012 Feb 2;119(5):1182-9
22180443
Blood. 2012 Mar 15;119(11):2590-4
22279054
Blood. 2012 Aug 9;120(6):1175-84
22715122
J Clin Oncol. 2013 Jan 1;31(1):88-94
23045577
Nat Med. 2013 Feb;19(2):202-8
23291630
Leuk Lymphoma. 2013 Nov;54(11):2385-91
23425038
Leukemia. 2013 Dec;27(12):2311-21
23619564
Blood. 2013 May 30;121(22):4439-42
23620577
N Engl J Med. 2013 Aug 8;369(6):507-16
23782157
N Engl J Med. 2013 Jul 4;369(1):32-42
23782158
Blood. 2013 Oct 10;122(15):2539-49
23886836
Blood. 2013 Nov 7;122(19):3308-16
24009233
Blood. 2014 Feb 20;123(8):1207-13
24311722
Clin Cancer Res. 2014 Feb 1;20(3):548-56
24323900
Lancet Oncol. 2014 Jan;15(1):48-58
24332241
N Engl J Med. 2014 Mar 20;370(12):1101-10
24401022
Blood. 2014 Mar 20;123(12):1810-7
24415539
N Engl J Med. 2014 Mar 13;370(11):997-1007
24450857
Blood. 2014 Feb 20;123(8):1119-21
24558189
Blood. 2014 Mar 20;123(12):1957-60
24652965
Blood. 2014 May 22;123(21):3286-95
24659631
Leukemia. 2014 Nov;28(11):2188-96
24699307
Blood. 2014 Jun 12;123(24):3727-32
24705492
J Clin Oncol. 2014 Jun 10;32(17):1830-9
24778403
Blood. 2014 Jun 26;123(26):4132-5
24829205
N Engl J Med. 2014 Jun 12;370(24):2286-94
24869598
N Engl J Med. 2014 Jul 17;371(3):213-23
24881631
Future Oncol. 2014 May;10(6):957-67
24941982
J Clin Oncol. 2014 Sep 20;32(27):3039-47
25049322
Leukemia. 2015 Apr;29(4):783-7
25138588
Lancet Oncol. 2014 Sep;15(10):1090-9
25150798
J Natl Cancer Inst. 2014 Sep 10;106(9):null
25214559
Blood. 2014 Dec 18;124(26):3991-5
25305202
Leuk Lymphoma. 2015 Jun;56(6):1643-50
25308294
Cancer Chemother Pharmacol. 2015 Jan;75(1):111-21
25381051
Drug Metab Dispos. 2015 Feb;43(2):289-97
25488930
Blood. 2014 Dec 11;124(25):3829-30
25498454
MAbs. 2015;7(1):192-8
25523586
Lancet Oncol. 2015 Feb;16(2):169-76
25555420
Blood. 2015 Jan 8;125(2):407-10
25573971
Blood. 2015 Mar 26;125(13):2062-7
25573991
Haematologica. 2015 Apr;100(4):e140-2
25616578
Blood. 2015 Apr 16;125(16):2497-506
25700432
Cancer Chemother Pharmacol. 2015 May;75(5):907-16
25724156
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):E966-72
25730880
J Oncol Pract. 2015 May;11(3):252-8
25804983
Clin Cancer Res. 2015 Aug 15;21(16):3705-15
25829398
Blood. 2015 May 14;125(20):3128-32
25838351
N Engl J Med. 2015 Apr 9;372(15):1430-40
25853747
Blood. 2015 Jul 23;126(4):463-70
26065656
Blood. 2015 Jul 23;126(4):471-7
26065659
Clin Cancer Res. 2015 Oct 15;21(20):4642-51
26089373
Scand J Immunol. 2015 Sep;82(3):208-17
26111359
Blood. 2015 Aug 13;126(7):842-50
26116658
Pharmacol Res Perspect. 2015 Aug;3(4):e00156
26171235
JAMA Oncol. 2015 Aug;1(5):684-6
26182170
JAMA Oncol. 2015 Apr;1(1):80-7
26182309
Cancer. 2015 Oct 15;121(20):3612-21
26193999
Clin Cancer Res. 2015 Aug 15;21(16):3586-90
26275952
Cancer Res. 2015 Oct 1;75(19):4153-63
26282174
Clin Cancer Res. 2016 Jan 1;22(1):86-95
26283682
Blood. 2015 Nov 5;126(19):2213-9
26337493
Haematologica. 2015 Dec;100(12):1571-8
26430171
Leuk Lymphoma. 2016;57(6):1494-7
26440741
Blood. 2016 Jan 21;127(3):303-9
26492934
Blood. 2016 Jan 28;127(4):411-9
26542378
Blood. 2016 Jan 21;127(3):279-86
26576865
Leukemia. 2016 Apr;30(4):833-43
26582643
Int J Hematol. 2016 Jan;103(1):86-94
26588924
N Engl J Med. 2015 Dec 17;373(25):2425-37
26639149
N Engl J Med. 2016 Jan 28;374(4):311-22
26639348
N Engl J Med. 2016 Jan 28;374(4):323-32
26641137
Lancet Oncol. 2016 Feb;17(2):200-211
26655421
Clin Cancer Res. 2016 Apr 1;22(7):1572-82
26660519
Oncotarget. 2016 Jan 26;7(4):4598-610
26717038
JAMA Dermatol. 2016 Jun 1;152(6):698-701
26982511
Am J Dermatopathol. 2016 Jul;38(7):492-8
27043332
Thromb Res. 2016 Apr;140 Suppl 1:S196
27161742
Lancet Oncol. 2016 Jun;17(6):768-778
27178240
Leukemia. 2016 Aug;30(8):1803-4
27198052
Haematologica. 2016 Dec;101(12):1573-1580
27198718
Nat Commun. 2016 May 20;7:11589
27199251